A Phase 4 interventional study of Ferric Derisomaltose and Oral Iron (Ferrous sulphate) in Hip Fracture, Anemia and Iron, sponsored by University of Aarhus. Not yet recruiting at 5 sites in Denmark. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hip Fractures by University of Aarhus — 2 open to participants now, 2 under way, none of them phase 3. Hip Fractures · University of Aarhus.
Among the 12 studies in Hip Fractures by University of Aarhus, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 4, and was the 12th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →2 of the 12 studies in Hip Fractures by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 75+
By country, each count listing its studies:
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 528 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 37 across the 11 interventional studies, 447 across the 1 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
1 of the studies in Hip Fractures by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06938789University of AarhusHow Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Hip Fractures by University of Aarhus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.
The trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous iron once and placebo tablets on alternate days for 90 days
Drug: Ferric Derisomaltose · Drug: Placebo Tablets
Intravenous sodium chloride once and ferro sulfate tablets on alternate days for 90 days
Drug: Oral Iron (Ferrous sulphate) · Drug: Placebo IV
Intravenous sodium chloride once and placebo tablets on alternate days for 90 days
Drug: Placebo IV · Drug: Placebo Tablets
Intravenous Ferric Derisomaltose shortly after surgery and placebo tablets on alternate days for 90 days
Oral iron sulfate on alternate days for 90 days and IV placebo once shortly after surgery
100 ml Sodium Chloride (NaCl)
Placebo tablets on alternate days for 90 days
Fatigue
Measured by Multidimensional Fatigue Inventory tool (MFI-20). MFI-20 is a questionnaire of 20 questions answered on a 5-point scale from "yes, that is true" (1 point) to "no, that is not true" (5 points). A higher score indicates greater severity of fatigue.
Time frame: Baseline and days 30 and 90 after discharge
Hemoglobin increment
Defined as a change of level of a minimum of 1.24 mmol/L (2 g/dL). The level of hemoglobin will be measured with a venous blood sample
Time frame: Baseline and days 30 and 90 after discharge
Safety profile
Measured as the prevalence and severity of adverse events associated with iron treatment
Time frame: Days 15, 30, 45 and 90 after discharge
Physical function - NMS
New Mobility score (NMS) is used to assess the participant's mobility. The participant will be asked three questions ranging from "no difficult and no walking aid" (3 points) to "not able to at all" (0 points). The score ranges from 0 - 9 points. A higher score indicates a higher level of independent mobility.
Time frame: Baseline and days 30 and 90 after discharge
Physical function - handgrip strength
Handgrip strength is measured by using a dynamometer that measures the pressure made from a hand grip on the dynamometer in kilograms. A higher score indicates higher handgrip strength.
Time frame: Baseline and days 30 and 90 after discharge.
Physical function - 30 second sit-to-stand-test
30 second sit-to-stand-test is used as a parameter for strength, muscle power and dynamic balance. The test is performed by placing a chair with the back against a wall. The participant must be seated on the chair with their arms crossed and are then encouraged to fully stand and sit as many times as possible in 30 seconds. If the arms are used to stand, the score will be 0. A low score indicates low physical ability, and a higher score indicates high physical ability.
Time frame: Baseline and days 30 and 90 after discharge.
Fear of Falling
Measured by Short Fall Efficiency Scale-International which is a 7 questions questionnaire assessing the fear of falling from 7 points (low concern of falling) to 28 points (high concern of falling).
Time frame: Days 30 and 90 after discharge
Cognitive impairment
Measured by Brief Assessment of Impaired Cognition (BASIC). The tool consists of three questions to the patient (0-6 points), word finding (0-5 points), categorized recalling of photos (0-8 points) and lastly three questions to a next of kin (0-6 points). A low score indicates impaired cognition. In cases where no next of kins is available the conversion table is used of an estimated score according to the guidance from the Danish Dementia Research Centre.
Time frame: Baseline and days 30 and 90 after discharge
Quality of life
European Quality of Life - 5 Dimensions (EQ-5D-5L) which is a standardized questionnaire used to evaluate health-related quality of life. There are 5 questions ranging from level 1 - 5 Level 1 indicates: no problems Level 2 indicates: slight problems Level 3 indicates: moderate problems Level 4 indicates: severe problems Level 5 indicates: extreme problems And lastly a visual analogue scale from 0 - 100 where 100 means the best health imaginable and 0 means the worst health imaginable.
Time frame: Baseline and 90 days after discharge
Biochemical iron status - transferrin
p-transferrin (μmol/L) measured by a venous blood sample.
Time frame: Baseline and on days 30 and 90 after discharge
Biochemical iron status - ferritin
p-ferritin (μg/L) measured by a venous blood sample
Time frame: Baseline and on days 30 and 90 after discharge
Plan to share: Yes — Upon relevant request
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 23 months is close to that.
Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iron isomaltoside 1000 · Iron